3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
30
Carcinoma, Renal Cell
17
Prostatic Neoplasms
13
Carcinoma, Transitional Cell
11
Melanoma
8
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
7
Uterine Cervical Neoplasms
6
Kidney Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
5
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Urothelial Cancer
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma in Situ
2
Carcinoma
2
Interventions
tislelizumab
2
Cystectomy
2
vistusertib
1
toripalimab
1
olaparib
1
liposomal doxorubicin
1
durvalumab
1
disitamab vedotin
1
danvatirsen
1
adavosertib
1
Surgical Procedures, Operative
1
Rutin
1
Radiation
1
RC48 antibody
1
Neoadjuvant Therapy
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
durvalumab
×
Genitourinary
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled